EUVIMEDEUVIMED entdecken
Übersichtsarbeit

mRNA therapeutics: Molecular mechanisms, delivery platforms, regulatory frameworks, and equitable global access

Taruna Ikrar, Wachyudi Muchsin, Alfi Sophian

Journal of Controlled Release · 2026-07 · 395 · 115019

DOI: 10.1016/j.jconrel.2026.115019 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2026-07. Verfasst von Taruna Ikrar und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Indonesian Food and Drug Authority (BPOM), Jl. Percetakan Negara No. 23, Jakarta Pusat 10560, Indonesia. Hauptthemen laut MEDLINE: RNA, Messenger, Drug Delivery Systems. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 102 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Messenger RNA (mRNA) therapeutics represent a transformative pharmaceutical modality, with three products approved by 2024 across infectious disease and rare metabolic indications. This review critically examines: (i) mRNA molecular architecture including nucleoside modification strategies for immune evasion and platforms beyond conventional mRNA (self-amplifying RNA [saRNA], circular RNA); (ii) lipid nanoparticle (LNP) delivery mechanisms encompassing endosomal escape limitations, selective organ targeting (SORT), and emerging alternative delivery systems including single-component carriers; (iii) the clinical application landscape spanning vaccines, personalised cancer immunotherapy, protein replacement, and CRISPR genome editing; (iv) translational challenges including stability, tissue-targeting, immunogenicity, and manufacturing scalability; and (v) the critically underrepresented dimensions of regulatory science and equitable global access in low- and middle-income countries (LMICs), drawing on Indonesia's BPOM as a policy case study contextualised within the broader LMIC regulatory landscape. Concrete capacity-building recommendations - including establishment of regional mRNA reference standard laboratories, low-cost dsRNA analytical platforms, and harmonised pharmacovigilance systems - are proposed. This review provides a molecularly grounded and policy-relevant synthesis for drug delivery scientists and regulators advancing equitable mRNA therapeutic access.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, MessengerDrug Delivery SystemsHumansAnimalsNanoparticles

Stichwörter der Autor:innen

Genome editingLipid nanoparticleLow-income countriesNucleoside modificationProtein replacementRegulatory sciencecancer immunotherapymRNA

Substanzen

RNA, Messenger

Autor:innen und Institutionen

  • The Indonesian Food and Drug Authority (BPOM), Jl. Percetakan Negara No. 23, Jakarta Pusat 10560, Indonesia.
  • The Indonesian Food and Drug Authority (BPOM), Jl. Percetakan Negara No. 23, Jakarta Pusat 10560, Indonesia. Electronic address: alfi.sophian@pom.go.id.

Zitieren

APA

Ikrar, T., Muchsin, W., & Sophian, A. (2026). mRNA therapeutics: Molecular mechanisms, delivery platforms, regulatory frameworks, and equitable global access. Journal of Controlled Release, 395, 115019. https://doi.org/10.1016/j.jconrel.2026.115019

Vancouver

Ikrar T, Muchsin W, Sophian A. mRNA therapeutics: Molecular mechanisms, delivery platforms, regulatory frameworks, and equitable global access. Journal of Controlled Release. 2026;395:115019. doi:10.1016/j.jconrel.2026.115019

BibTeX
@article{Ikrar2026,
  author = {Ikrar, Taruna and Muchsin, Wachyudi and Sophian, Alfi},
  title = {mRNA therapeutics: Molecular mechanisms, delivery platforms, regulatory frameworks, and equitable global access},
  journal = {Journal of Controlled Release},
  year = {2026},
  volume = {395},
  pages = {115019},
  doi = {10.1016/j.jconrel.2026.115019}
}
Kostenlos starten →